Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

LCA-0321 is a LYTAC degrader designed to specifically bind and rapidly deplete anti-TSHR autoantibodies, the underlying cause of Graves’ disease and its extrathyroidal manifestations, including ...

Stephanie Diaz; Investor Relations Manager; Viking Therapeutics Inc. Brian Lian; President, Chief Executive Officer, Director; Viking Therapeutics Inc. Greg Zante; C ...

Thyroid disease is often missed in older adults because its symptoms overlap with those of “normal aging.” In this ...

Fintel reports that on February 7, 2025, Citigroup initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Neutral ...

The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, when a causative role of the drug is implausible, suggested stepped-up ...

TH receptors are nuclear transcription factors ... investigators at the 8 th International Workshop on Resistance to Thyroid Hormone... Recent discoveries of genetic defects that reduce the ...

Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Viking Therapeutics in a research note issued on Thursday, February 6th. HC Wainwright analyst J. Pantginis expects that ...

The program emphasizes a deep assessment of cellular health and the removal of toxins to restore proper thyroid function and overall well-being. Hormone Receptor Blockage and Its Impact on Thyroid ...

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...

Viking Therapeutics (NASDAQ:VKTX – Get Free Report) is expected to release its earnings data after the market closes on Wednesday, February 5th. Analysts expect Viking Therapeutics to post earnings of ...